Cargando…
Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies
BACKGROUND: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends a short-acting bronchodilator or single long-acting bronchodilator as an initial pharmacological treatment for GOLD category A patients with COPD. We pooled data from the PINNACLE-1, -2, and -4 studies to evalua...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6957003/ https://www.ncbi.nlm.nih.gov/pubmed/32021148 http://dx.doi.org/10.2147/COPD.S229794 |
_version_ | 1783487244280004608 |
---|---|
author | Martinez, Fernando J Rabe, Klaus F Lipworth, Brian J Arora, Samir Jenkins, Martin Martin, Ubaldo J Reisner, Colin |
author_facet | Martinez, Fernando J Rabe, Klaus F Lipworth, Brian J Arora, Samir Jenkins, Martin Martin, Ubaldo J Reisner, Colin |
author_sort | Martinez, Fernando J |
collection | PubMed |
description | BACKGROUND: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends a short-acting bronchodilator or single long-acting bronchodilator as an initial pharmacological treatment for GOLD category A patients with COPD. We pooled data from the PINNACLE-1, -2, and -4 studies to evaluate the efficacy and safety of the dual bronchodilator fixed-dose combination glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI), formulated using co-suspension delivery technology, in GOLD category A patients with moderate-to-very severe COPD. MATERIALS AND METHODS: PINNACLE-1, -2, and -4 were Phase III, randomized, double-blind, parallel-group, multicenter studies (NCT01854645, NCT01854658, and NCT02343458). Patients received 24 weeks’ treatment with GFF MDI 18/9.6 µg, glycopyrrolate (GP) MDI 18 µg, formoterol fumarate (FF) MDI 9.6 µg, or placebo MDI twice daily. GOLD category A patients were identified based on a COPD Assessment Test score of <10 and exacerbation history in the previous year (none/one not requiring hospitalization). Endpoints evaluated were change from baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV(1)), peak change from baseline in FEV(1) within 2 hrs post-dose, and adverse events (AEs). RESULTS: The pooled intent-to-treat population comprised 729 GOLD category A patients. GFF MDI significantly improved morning pre-dose trough FEV(1) at Week 24 versus GP MDI, FF MDI, and placebo MDI (least squares mean [LSM] differences 54 mL, 62 mL, and 188 mL, respectively; all p≤0.0053), and peak FEV(1) at Week 24 versus GP MDI, FF MDI, and placebo MDI (LSM differences 124 mL, 104 mL, and 307 mL, respectively; all p<0.0001). Improvements over 24 weeks were comparable to at Week 24. The AE profile of GFF MDI in GOLD category A patients was similar to monocomponents and placebo MDI. CONCLUSION: GFF MDI significantly improved lung function versus monocomponents and placebo MDI in GOLD category A patients with moderate-to-very severe COPD, with no unexpected safety findings. |
format | Online Article Text |
id | pubmed-6957003 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-69570032020-02-04 Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies Martinez, Fernando J Rabe, Klaus F Lipworth, Brian J Arora, Samir Jenkins, Martin Martin, Ubaldo J Reisner, Colin Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends a short-acting bronchodilator or single long-acting bronchodilator as an initial pharmacological treatment for GOLD category A patients with COPD. We pooled data from the PINNACLE-1, -2, and -4 studies to evaluate the efficacy and safety of the dual bronchodilator fixed-dose combination glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI), formulated using co-suspension delivery technology, in GOLD category A patients with moderate-to-very severe COPD. MATERIALS AND METHODS: PINNACLE-1, -2, and -4 were Phase III, randomized, double-blind, parallel-group, multicenter studies (NCT01854645, NCT01854658, and NCT02343458). Patients received 24 weeks’ treatment with GFF MDI 18/9.6 µg, glycopyrrolate (GP) MDI 18 µg, formoterol fumarate (FF) MDI 9.6 µg, or placebo MDI twice daily. GOLD category A patients were identified based on a COPD Assessment Test score of <10 and exacerbation history in the previous year (none/one not requiring hospitalization). Endpoints evaluated were change from baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV(1)), peak change from baseline in FEV(1) within 2 hrs post-dose, and adverse events (AEs). RESULTS: The pooled intent-to-treat population comprised 729 GOLD category A patients. GFF MDI significantly improved morning pre-dose trough FEV(1) at Week 24 versus GP MDI, FF MDI, and placebo MDI (least squares mean [LSM] differences 54 mL, 62 mL, and 188 mL, respectively; all p≤0.0053), and peak FEV(1) at Week 24 versus GP MDI, FF MDI, and placebo MDI (LSM differences 124 mL, 104 mL, and 307 mL, respectively; all p<0.0001). Improvements over 24 weeks were comparable to at Week 24. The AE profile of GFF MDI in GOLD category A patients was similar to monocomponents and placebo MDI. CONCLUSION: GFF MDI significantly improved lung function versus monocomponents and placebo MDI in GOLD category A patients with moderate-to-very severe COPD, with no unexpected safety findings. Dove 2020-01-09 /pmc/articles/PMC6957003/ /pubmed/32021148 http://dx.doi.org/10.2147/COPD.S229794 Text en © 2020 Martinez et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Martinez, Fernando J Rabe, Klaus F Lipworth, Brian J Arora, Samir Jenkins, Martin Martin, Ubaldo J Reisner, Colin Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies |
title | Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies |
title_full | Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies |
title_fullStr | Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies |
title_full_unstemmed | Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies |
title_short | Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies |
title_sort | glycopyrrolate/formoterol fumarate metered dose inhaler improves lung function versus monotherapies in gold category a patients with copd: pooled data from the phase iii pinnacle studies |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6957003/ https://www.ncbi.nlm.nih.gov/pubmed/32021148 http://dx.doi.org/10.2147/COPD.S229794 |
work_keys_str_mv | AT martinezfernandoj glycopyrrolateformoterolfumaratemetereddoseinhalerimproveslungfunctionversusmonotherapiesingoldcategoryapatientswithcopdpooleddatafromthephaseiiipinnaclestudies AT rabeklausf glycopyrrolateformoterolfumaratemetereddoseinhalerimproveslungfunctionversusmonotherapiesingoldcategoryapatientswithcopdpooleddatafromthephaseiiipinnaclestudies AT lipworthbrianj glycopyrrolateformoterolfumaratemetereddoseinhalerimproveslungfunctionversusmonotherapiesingoldcategoryapatientswithcopdpooleddatafromthephaseiiipinnaclestudies AT arorasamir glycopyrrolateformoterolfumaratemetereddoseinhalerimproveslungfunctionversusmonotherapiesingoldcategoryapatientswithcopdpooleddatafromthephaseiiipinnaclestudies AT jenkinsmartin glycopyrrolateformoterolfumaratemetereddoseinhalerimproveslungfunctionversusmonotherapiesingoldcategoryapatientswithcopdpooleddatafromthephaseiiipinnaclestudies AT martinubaldoj glycopyrrolateformoterolfumaratemetereddoseinhalerimproveslungfunctionversusmonotherapiesingoldcategoryapatientswithcopdpooleddatafromthephaseiiipinnaclestudies AT reisnercolin glycopyrrolateformoterolfumaratemetereddoseinhalerimproveslungfunctionversusmonotherapiesingoldcategoryapatientswithcopdpooleddatafromthephaseiiipinnaclestudies |